Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
Drug Therapy01:28

Drug Therapy

43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
43
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

636
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
636
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.8K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.1K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

586
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
586

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current State of Computed Tomography Derived Fractional Flow Reserve (FFR-CT) and Its Diagnostic Advantages.

Clinical Medicine Insights. Cardiology·2026
Same author

De-risking Atrial Fibrillation: Refining Anticoagulation Decision-Making.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2026
Same author

The burden and outcomes of vaccine-preventable infections among adult congenital heart disease patients: a nationwide analysis.

Proceedings (Baylor University. Medical Center)·2026
Same author

Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.

The American journal of cardiology·2026
Same author

The Problem of Suffering.

Annals of internal medicine·2026
Same author

Impact of Peri-Procedural Red Blood Cell Transfusion on Clinical Outcomes in Transcatheter Aortic Valve Replacement: A Propensity-Matched Cohort Study.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

Related Experiment Video

Updated: Jul 1, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Updates on Non-Statin LDL-Lowering Therapy.

Amer Abdulla1, Mostafa Shalaby2, Paul Kumfa2

  • 1, 301 University Blvd., JSA 5.106G, Galveston, TX, 77555-0553, USA. ameabdul@utmb.edu.

Current Cardiology Reports
|March 4, 2024
PubMed
Summary

New non-statin therapies effectively lower low-density lipoprotein (LDL) cholesterol, reducing cardiovascular events. These agents, including ezetimibe and PCSK9 inhibitors, offer safe and effective options for patients needing additional LDL reduction.

Keywords:
Bempedoic acidEzetimibeHyperlipidemiaInclisiranLow-density lipoproteinProprotein convertase subtilisin/kexin type 9 inhibitor

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.4K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.0K

Related Experiment Videos

Last Updated: Jul 1, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.4K
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.0K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality.
  • Low-density lipoprotein (LDL) cholesterol is a primary target for ASCVD prevention.
  • Statins are first-line therapy, but many patients require additional LDL-lowering strategies.

Purpose of the Study:

  • To review current non-statin LDL-lowering therapies.
  • To discuss their mechanisms of action, efficacy, and safety.
  • To provide clinical practice recommendations for their use.

Main Methods:

  • Narrative review of available non-statin LDL-lowering agents.
  • Analysis of data from randomized controlled trials and expert consensus.

Main Results:

  • Ezetimibe, PCSK9 inhibitors, and bempedoic acid are safe and effective in reducing cardiovascular events.
  • Inclisiran shows promise in suppressing PCSK9 and is under clinical investigation.
  • Expert consensus supports lower LDL targets and combination therapy for high-risk patients.

Conclusions:

  • Non-statin therapies are valuable additions to the LDL-lowering armamentarium.
  • These agents enable achievement of lower LDL targets in high-risk individuals.
  • Personalized treatment strategies incorporating non-statin agents are crucial for ASCVD prevention.